Drug
Telapristone acetate clinical trials
Also written Proellex and CDB-4124.
- studies test it
- 35
- open now
- 0
- in phase 3
- 7
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2008 (12)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 12 |
| 2009 | 5 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 19
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 2
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses telapristone acetate is read from its arms, and is right about nine times in ten.
Testing it · 35
- Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing MastectomyCompletedPhase 2Northwestern UniversityNCT02314156Written as Telapristone Acetate
- Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast CancerStatus unknownPhase 2Northwestern UniversityNCT01800422Written as telapristone acetate
- Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic EndometriosisCompletedPhase 2Repros Therapeutics Inc.NCT01728454Written as Telapristone acetate
- An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsTerminatedPhase 2Repros Therapeutics Inc.NCT02811159Written as Telapristone acetate
- Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine FibroidsCompletedPhase 2Repros Therapeutics Inc.NCT02323646Written as Telapristone Acetate
- Proellex® Pharmacokinetic Bridging Study IICompletedPhase 1Repros Therapeutics Inc.NCT00620503Written as Proellex 25 mg formulation A
- A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsCompletedPhase 2Repros Therapeutics Inc.NCT02301897Written as Telapristone Acetate
- Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003CompletedPhase 2Repros Therapeutics Inc.NCT00958334Written as Proellex®
- Crossover Study of the Safety and PK Properties of Proellex®CompletedPhase 1Repros Therapeutics Inc.NCT00749879Written as Proellex
- Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension StudyTerminatedPhase 2Repros Therapeutics Inc.NCT00958412Written as Proellex®
- Comparison of Two Formulations of Proellex for Oral AdministrationCompletedPhase 1Repros Therapeutics Inc.NCT02141061Written as Telapristone Acetate, Proellex 12 mg Formulation A
- Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine FibroidsCompletedPhase 2Repros Therapeutics Inc.NCT01451424Written as Proellex
- Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy AdultsCompletedPhase 1Repros Therapeutics Inc.NCT00741273Written as Proellex
- Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy FemalesTerminatedPhase 1/2Repros Therapeutics Inc.NCT00787618Written as 50 mg Proellex
- Study to Evaluate Menses Induction in Women Administered ProellexTerminatedPhase 1Repros Therapeutics Inc.NCT00881608Written as Proellex
- Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic EndometriosisTerminatedPhase 2Repros Therapeutics Inc.NCT00556075Written as Proellex 25 mg
- An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 ExtTerminatedPhase 2Repros Therapeutics Inc.NCT00958893Written as 25 mg Proellex
- Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female SubjectsCompletedPhase 1Repros Therapeutics Inc.NCT00741468Written as Proellex
- Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine FibroidsTerminatedPhase 3Repros Therapeutics Inc.NCT01069120Written as Proellex
- Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine FibroidsTerminatedPhase 3Repros Therapeutics Inc.NCT00737282Written as Proellex 25 mg
Codes
What other systems call telapristone acetate · ClinicalTrials.gg INT004461
- MeSH (NLM) C461063telapristone acetateOne source NLM
- UNII (FDA) 1K9EYK92PQTELAPRISTONE ACETATEConfirmed FDA, NLM, Wikidata
- Wikidata Q7695644telapristone acetateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104055Telapristone AcetateOne source FDA
- DrugBank DB05253One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C461063 | telapristone acetate | One source NLM |
| UNII (FDA) | 1K9EYK92PQ | TELAPRISTONE ACETATE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7695644 | telapristone acetate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104055 | Telapristone Acetate | One source FDA |
| DrugBank | DB05253 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.